Avidity Biosciences — Investor Day (May 2021)
47 slides from Avidity Biosciences's investor day presentation, May 19, 2021
Slide 1: Virtual Investor & Analyst Event Series – Volume 1: Engineering AOCs
Virtual Investor & Analyst Event Series – Volume 1 Engineering AOC’s Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of
Slide 3: Our Vision
Our Vision To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1
Slide 4: Delivering on Our Vision
Delivering on Our Vision Progressing robust pipeline in muscle Entering the clinic with AOC 1001 in 2H 2021 Planning clinical initiations for both AOC 1044 in DMD and our AOC FSHD program in 2022 Leveraging expertise in clinical and commercial execution Assembling an experienced team in rare & RNA t
Slide 5: Advancing our Muscle Disease Franchise of AOCs
PROGRAM / INDICATION TARGET DISCOVERY / LEAD OPTIMIZATION IND ENABLING CLINICAL MUSCLE DISORDERS AOC 1001: Myotonic Dystrophy Type 1 (DM1) DMPK AOC FSHD: Facioscapulohumeral Muscular Dystrophy (FSHD) DUX4 AOC 1044: Duchenne Muscular Dystrophy (DMD) Exon 44 Dystrophin Next AOC DMD Programs Exon 51 Dy
Slide 6: Goals for the Day
Goals for the Day Provide a deep dive into the years of engineering supporting our AOCTM platform Demonstrate how we are delivering on the power of the platform through our pipeline Offer a broader perspective on the history and future of RNA therapeutics Take your questions mAb OLIGO
Slide 7: What's New: Highlights from Today
What’s New: Deep Dive on the AOC Platform: Demonstrating data-driven choices in engineering each component of our AOCs Showing the previously unseen data used to choose a mAb AOC 1001 safety profile supports entry into the clinic: Sharing additional Non-GLP data Presenting outcomes and data from our
Slide 8: Agenda
Agenda Welcome & Introduction Engineering the Future of RNA Therapeutics Translating RNA Research Into Medicines Q&A Session Closing Remarks Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO (Moderator) Steven F. Dowdy, Ph.D., UCSD Phillip D. Zamore, Ph.D., UMASS Art Levin
Slide 9: Avidity Management Team Participants
Avidity Management Team Participants Art Levin, Ph.D. Chief Scientific Officer Art Levin is an expert in the RNA therapeutics field who led teams responsible for the development of many oligonucleotides. He serves as the Chief Scientific Officer at Avidity Biosciences. Previously, he held the positi
Slide 10: Agenda
Agenda Welcome & Introduction Engineering the Future of RNA Therapeutics Translating RNA Research Into Medicines Q&A Session Closing Remarks Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO (Moderator) Steven F. Dowdy, Ph.D., UCSD Phillip D. Zamore, Ph.D., UMASS Art Levin
Slide 11: Engineering the Future of RNA Therapeutics
Engineering the Future of RNA Therapeutics Art Levin, Ph.D., CSO
Slide 12: Established delivery mechanism and built a pipeline of AOCs
PIPELINE Established delivery mechanism and built a pipeline of AOCs AVIDITY FOUNDING Founded to solve delivery challenge of oligonucleotides We Followed the Data to AOCs TRANSFERRIN Solidified as first transporter ANTIBODY-OLIGO CONJUGATES Demonstrated more efficient, targeted delivery Antibody-tar
Slide 13: Engineering AOCs: Following the Data
Engineering AOCs: Following the Data AOCs: Engineering the delivery of RNA therapies AOC 1001: First clinical proof-of-concept program beginning in 2H 2021 Delivering Next: AOCs in rare muscle diseases…and beyond mAb OLIGO
Slide 14: AOCs - A Powerful New Class of Drugs
AOCs - A Powerful New Class of Drugs We employ mAbs to cell surface receptors for targeted delivery of oligonucleotides to a range of cell types and tissues Our AOCs combine the proven and safe technologies of monoclonal antibodies and oligonucleotides Specificity of targeting with mAbs Potency & pr
Slide 15: Following the Data: Choosing a mAb to Expand Delivery Beyond the Liver
Following the Data: Choosing a mAb to Expand Delivery Beyond the Liver mAbs Offer Safe and Effective Targeting to Many Cells and Tissues Plasma PK in a Non-Human Primate To deliver oligonucleotide therapeutics, we followed the data to select the delivery moiety Experiments showed that mAbs are super
Slide 16: Following the Data: Engineering the Linker
Following the data: Engineering the Linker Our Linkers are Optimized for Stability and Durability In addition to engineering our linker, we optimize several other key aspects including: sites of conjugation the ratio of oligonucleotides to antibodies AOCs with Different Linkers at 0.5 mg/kg in Mouse
Slide 17: Following the Data: Choosing the Oligonucleotide
Following the data: Choosing the Oligonucleotide siRNA was a deliberate choice based on safety, potency and efficacy Selected siRNAs for activity and specificity and engineered them to withstand lysosomal enzymes siRNAs are well characterized Attractive safety profile with no known thrombocytopenia,
Slide 18: Utilizing Multiple Non-Human Primate Studies to Inform Clinical Studies
Following the Data: Utilizing Multiple Non-Human Primate Studies to Inform our Clinical Studies Studies Key Hypothesis Tested NHP Study 1 & 2 Delivery moiety – Fab vs mAb NHP Study 3 Selection of lead mAb NHP Study 4 & 5 Selection of lead DMPK siRNA NHP Study 6 Non-GLP tox study of AOC 1001 at singl
Slide 19: Each Component was Engineered to Deliver the Optimal AOC
AOC COMPONENTS DATA-DRIVEN COMPONENT CHARACTERISTICS OUR ENGINEERING IMPACT Monoclonal antibody Well-established safety profile High specificity and affinity Long half-life Optimized through engineering to be effector function null Epitope selection for optimal activity Linker Known linker Applicabl
Slide 20: Engineering AOCs: Following the Data
Engineering AOCs: Following the Data AOCs: Engineering the delivery of RNA therapies AOC 1001: First clinical proof-of-concept program beginning in 2H 2021 Next AOCs: Rare muscle diseases…and beyond mAb OLIGO
Slide 21: DM1 is Well Suited to an siRNA Approach
DM1, Caused by a Toxic Gain-of-Function mRNA, is Well Suited to an siRNA Approach (CUG) n DMPK DMPK mRNA DM1 Disease Manifestations Misprocessed RNAs Protein Errors CUG MBNL MBNL MBNL Mutant DMPK mRNA Toxic Gain-of-Function MECHANISM OF DISEASE: DM1 is Caused by a Toxic Gain-of-Function of the Mutan
Slide 22: The AOC 1001 siRNA is Active in the Nucleus and Cytoplasm
The AOC 1001 siRNA is Active in the Nucleus and Cytoplasm DMPK expression % of mock treatment Cytoplasmic fraction Nuclear fraction Whole cell extract Control siDMPK.19 Nuclear and Cytoplasmic DMPK mRNA Levels in DM1 Patient-Derived Muscle Cells; Data: N=2 mean with range DM1 Patient Cells
Slide 23: DMPK-Targeted siRNA Reduces Nuclear Foci in DM1 Cells
DMPK-Targeted siRNA Reduces Nuclear Foci in DM1 Patient-Derived Muscle Cells Reduction of Nuclear Foci Containing Mutant DMPK mRNA DMPK RNA Foci MBNL1 DM1 Patient Cells
Slide 24: 56% Improvement in Splicing in DM1 Myotubes
The AOC 1001 siRNA (siDMPK.19) Produced a 56% Improvement in Splicing in DM1 Myotubes Treatment Signature (100 Splicing Events)
Slide 25: Durable ~75% Reduction of DMPK mRNA in Monkey Skeletal Muscles
% DMPK mRNA Expression in Cynomolgus Monkey Time (weeks) Quadriceps Gastrocnemius Durable ~75% Reduction of DMPK mRNA in Monkey Skeletal Muscles After a Single Dose of 2mg/kg of siDMPK.19
Slide 26: Durable DMPK Reductions in Cardiac Muscle and Diaphragm
Robust and Durable Reductions of DMPK Levels in Cardiac Muscle and Diaphragm After a Single Dose DMPK mRNA Expression in Cynomolgus Monkey (% PBS Control) siRNA Dose (mg/kg) Heart Diaphragm Weeks DMPK mRNA Expression in Cynomolgus Monkey (% PBS Control) Dose Response at Week 6 2 mg/kg at Week 12
Slide 27: AOC 1001 siRNA Reduces DMPK mRNA in Skeletal Muscle at Nanomolar Concentrations
The AOC 1001 siRNA Reduces DMPK mRNA in a Wide Range Skeletal Muscle at Nanomolar Concentrations DMPK Expression in Skeletal Muscle and GI After a Single i.v. Dose in Monkey
Slide 28: No Neutralizing Antibodies to AOC 1001 in NHP Study 6
Plasma Profiles Demonstrate No Neutralizing Antibodies to AOC 1001 in NHP Study 6 Study Termination 15 mg/kg 5 mg/kg 1.5 mg/kg Plasma half-life at 5 mg/kg ~ 24hrs No change in peak levels or slopes with repeated dosing, indicating an absence of neutralizing antibodies No accumulation with repeated d
Slide 29: AOC 1001 Reduces Muscle DMPK mRNA in Concentration Responsive Manner
AOC 1001 Reduces Muscle DMPK mRNA in Concentration Responsive Manner in Non-human Primates Terminal necropsy was at 7 weeks, following 3 doses at 0, 3, and 6 weeks EC50<0.1 nM Day 21 or 28 Post Dosing NHP Study 6
Slide 30: AOC 1001 GLP Toxicology Study
AOC 1001 GLP Toxicology Study
Slide 31: AOC 1001 Safety Profile Supports Entry into the Clinic
AOC 1001 Safety Profile Supports Entry into the Clinic No dose limiting toxicity observed in monkey at the highest dose tested No platelet or renal toxicity No treatment-related histopathologic toxicity in monkey No changes in safety pharmacology parameters (cardiac, respiratory and neurological) NO
Slide 32: AOC 1001 GLP Toxicology Study Design
AOC 1001 GLP Toxicology Study Design 13-Week GLP toxicology studies in cynomolgus monkeys (low, medium and high doses of siRNA every 6 weeks) Evaluated AOC 1001 at highest dose tested Key endpoints included: safety pharmacology parameters (cardiac, respiratory and neurological) standard safety endpo
Slide 33: >80% Reductions of DMPK mRNA in Skeletal Muscle at 13 Weeks
AOC 1001 Produced >80% Reductions of DMPK mRNA in Skeletal Muscle at 13 Weeks of Treatment in Monkey No adverse effects associated with DMPK mRNA reduction Skeletal Muscle LD = Latissimus Dorsi, VL = Vastus Lateralis Cardiac Muscle DMPK mRNA reductions in left ventricle and diaphragm of >75% > 80% D
Slide 34: AOC 1001 Has Been Engineered for Optimal Therapeutic Profile
AOC 1001 Has Been Engineered for Optimal Therapeutic Profile APPROACHING THE CLINIC Planned Phase 1/2 study initiation in H2 2021 DELIVERING ON DM1 Delivers RNA therapeutic to skeletal muscle Reduces target mRNA in a broad range of muscles in a dose dependent manner EC50s in muscle biopsies are in t
Slide 35: Engineering AOCs: Following the Data
Engineering AOCs: Following the Data AOCs: Engineering the delivery of RNA therapies AOC 1001: First clinical proof-of-concept program beginning in 2H 2021 Delivering next: AOCs in rare muscle diseases…and beyond mAb OLIGO
Slide 36: Advancing our Muscle Disease Franchise of AOCs
PROGRAM / INDICATION TARGET DISCOVERY / LEAD OPTIMIZATION IND ENABLING CLINICAL MUSCLE DISORDERS AOC 1001: Myotonic Dystrophy Type 1 (DM1) DMPK AOC FSHD: Facioscapulohumeral Muscular Dystrophy (FSHD) DUX4 AOC 1044: Duchenne Muscular Dystrophy (DMD) Exon 44 Dystrophin Next AOC DMD Programs Exon 51 Dy
Slide 37: AOCs Engineered to Use Receptor Mediated Uptake for a Range of Tissue and Cell Types
AOCs Engineered to Use Receptor Mediated Uptake for a Range of Tissue and Cell Types In Vivo SKELETAL MUSCLE CARDIAC IMMUNOLOGY IMMUNO-ONCOLOGY LIVER
Slide 38: Engineering AOCs: Following the Data to Deliver RNA
Engineering AOCs: Following the Data to Deliver RNA AOCs deliver RNA therapeutics with specificity, potency and precision AOCs are the result of years of in-house engineering AOCs exploit the well characterized safety and efficacy profiles of mAbs and siRNAs AOC 1001 – first clinical proof-of-concep
Slide 39: Agenda
Agenda Welcome & Introduction Engineering the Future of RNA Therapeutics Translating RNA Research Into Medicines Q&A Session Closing Remarks Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO (Moderator) Steven F. Dowdy, Ph.D., UCSD Phillip D. Zamore, Ph.D., UMASS Art Levin
Slide 40: KOL Panel: Translating RNA Research Into Medicines
KOL Panel: Translating RNA Research Into Medicines Panelists: Steven F. Dowdy, Ph.D., UCSD Phillip D. Zamore, Ph.D., UMASS Art Levin, Ph.D., CSO Moderator:Mike Flanagan, Ph.D., CTO
Slide 41: Panelists: Translating RNA Research Into Medicines
Panelists: Translating RNA Research Into Medicines Phillip D. Zamore, Ph.D., the Gretchen Stone Cook Professor of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Investigator of the Howard Hughes Medical Institute, is Chair of the RNA Therapeutics Institute, which was
Slide 42: Agenda
Agenda Welcome & Introduction Engineering the Future of RNA Therapeutics Translating RNA Research Into Medicines Q&A Session Closing Remarks Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO (Moderator) Steven F. Dowdy, Ph.D., UCSD Phillip D. Zamore, Ph.D., UMASS Art Levin
Slide 43: Q&A Participants
Q&A Participants: Avidity Management Steven F. Dowdy, Ph.D., UCSD Phillip D. Zamore, Ph.D., UMASS Moderator: Art Levin, Ph.D., CSO
Slide 44: Agenda
Agenda Welcome & Introduction Engineering the Future of RNA Therapeutics Translating RNA Research Into Medicines Q&A Session Closing Remarks Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO (Moderator) Steven F. Dowdy, Ph.D., UCSD Phillip D. Zamore, Ph.D., UMASS Art Levin
Slide 45: Delivering on the RNA Revolution
Delivering on the RNA Revolution Sarah Boyce, President & CEO
Slide 46: Goals for the Day
Goals for the Day Provide a deep dive into the years of engineering underpinning our AOC platform Demonstrate how we are delivering on the power of the platform through: Engineering the optimal AOCs AOC 1001 - in clinic in 2H 2021 Progressing our pipeline Offer a broader perspective on the history a
Slide 47: Delivering on the RNA Revolution
Delivering on the RNA Revolution AOC 1001 into the clinic in H2 2021 FSHD & DMD programs in the clinic in 2022 Preclinical proof of concept in additional skeletal muscle and other tissues DELIVERING NEXT Luke Living with DM1